PE20110570A1 - Heterociclos biciclicos sustituidos - Google Patents

Heterociclos biciclicos sustituidos

Info

Publication number
PE20110570A1
PE20110570A1 PE2010001198A PE2010001198A PE20110570A1 PE 20110570 A1 PE20110570 A1 PE 20110570A1 PE 2010001198 A PE2010001198 A PE 2010001198A PE 2010001198 A PE2010001198 A PE 2010001198A PE 20110570 A1 PE20110570 A1 PE 20110570A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
heterocycles
cyclopropyl
amide
Prior art date
Application number
PE2010001198A
Other languages
English (en)
Spanish (es)
Inventor
Robert Andrew Heald
Philip Jackson
Joseph Lyssikatos
Stephen Price
Pierre Pascal Savy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41038842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20110570A1 publication Critical patent/PE20110570A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2010001198A 2008-07-01 2009-07-01 Heterociclos biciclicos sustituidos PE20110570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7742608P 2008-07-01 2008-07-01

Publications (1)

Publication Number Publication Date
PE20110570A1 true PE20110570A1 (es) 2011-08-26

Family

ID=41038842

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001198A PE20110570A1 (es) 2008-07-01 2009-07-01 Heterociclos biciclicos sustituidos

Country Status (15)

Country Link
US (1) US8841462B2 (enExample)
EP (1) EP2310373A1 (enExample)
JP (1) JP5544358B2 (enExample)
KR (1) KR20110029161A (enExample)
CN (1) CN102137847B (enExample)
AU (1) AU2009266956B2 (enExample)
BR (1) BRPI0910175A2 (enExample)
CA (1) CA2727250A1 (enExample)
CL (1) CL2010001641A1 (enExample)
IL (1) IL209931A0 (enExample)
MX (1) MX2010014559A (enExample)
PE (1) PE20110570A1 (enExample)
RU (1) RU2509078C2 (enExample)
WO (1) WO2010003025A1 (enExample)
ZA (1) ZA201008963B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101398772B1 (ko) 2009-11-04 2014-05-27 노파르티스 아게 Mek 억제제로서 유용한 헤테로시클릭 술폰아미드 유도체
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
EP2718276A1 (en) * 2011-06-09 2014-04-16 Novartis AG Heterocyclic sulfonamide derivatives
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
NO2714752T3 (enExample) 2014-05-08 2018-04-21
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN104119332B (zh) * 2014-07-08 2019-03-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
MX380283B (es) 2016-10-28 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN114760994A (zh) * 2019-12-04 2022-07-15 艾库斯生物科学有限公司 HIF-2α的抑制剂
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
CN113336786B (zh) * 2021-05-31 2022-10-18 南京工业大学 一种非对映选择性的多取代环烷基化合物及其制备方法
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017853C3 (de) 1970-04-14 1975-12-11 Standard Elektrik Lorenz Ag, 7000 Stuttgart Steuerverfahren zur Sicherung der Informationsverarbeitung und -Übertragung
ZA711710B (en) * 1970-05-28 1971-12-29 Squibb & Sons Inc Amino derivatives of purazolo-pyridine carboxylic acids and esters
US3736326A (en) * 1971-03-29 1973-05-29 Squibb & Sons Inc Isoxazolopyridine carboxylic acids and esters
US3780047A (en) * 1972-07-05 1973-12-18 Squibb & Sons Inc Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
ZA200407220B (en) 2002-03-13 2007-05-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
JP2005526076A (ja) 2002-03-13 2005-09-02 アレイ バイオファーマ、インコーポレイテッド Mek阻害剤としてのn3アルキル化ベンズイミダゾール誘導体
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ, インコーポレイテッド 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1689233B1 (en) 2003-11-19 2012-07-04 Array Biopharma, Inc. Bicyclic inhibitors of mek
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2004299438A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
EP1697336B1 (en) 2003-12-22 2007-12-19 Basilea Pharmaceutica AG Aroylfuranes and aroylthiophenes suitable for the treatment of cancer
JP2007516275A (ja) 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CN103524392B (zh) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
JP2010502650A (ja) 2006-08-31 2010-01-28 アレイ バイオファーマ、インコーポレイテッド Raf阻害化合物およびその使用法

Also Published As

Publication number Publication date
EP2310373A1 (en) 2011-04-20
US20110190257A1 (en) 2011-08-04
MX2010014559A (es) 2011-03-04
JP5544358B2 (ja) 2014-07-09
ZA201008963B (en) 2012-03-28
CL2010001641A1 (es) 2011-07-15
AU2009266956B2 (en) 2014-03-20
IL209931A0 (en) 2011-02-28
CN102137847B (zh) 2015-06-10
CN102137847A (zh) 2011-07-27
RU2011103454A (ru) 2012-08-10
BRPI0910175A2 (pt) 2017-03-21
US8841462B2 (en) 2014-09-23
JP2011526926A (ja) 2011-10-20
RU2509078C2 (ru) 2014-03-10
AU2009266956A1 (en) 2010-01-07
WO2010003025A1 (en) 2010-01-07
KR20110029161A (ko) 2011-03-22
CA2727250A1 (en) 2010-01-07
AU2009266956A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
PE20110570A1 (es) Heterociclos biciclicos sustituidos
AR110992A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
PE20091523A1 (es) Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
EA201000297A1 (ru) Конденсированные бициклические имидазолы
EA201070864A1 (ru) Новые гетероциклические соединения
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
EA201170520A1 (ru) Ингибитор p38 mapk-киназы
EA201991122A1 (ru) 3-ЗАМЕЩЕННЫЕ ПРОПАНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV
UA104449C2 (uk) Комбінація, що містить метотрексат та інгібітор дгодг
PH12012500643A1 (en) Novel phenol derivative
AR076798A1 (es) Pirazinilpirazoles y composiciones que comprenden dichos compuestos
PE20090444A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc
WO2015081349A3 (en) Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides
EA202091803A1 (ru) Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
PE20071318A1 (es) Derivados nuevos de urea ciclica, su preparacion y su utilizacion farmaceutica como inhibidores de cinasas
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
SA522432710B1 (ar) مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
MX2020002571A (es) Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2 -ol y compuestos relacionados como inhibidores de il-17 e ifn-gamma para tratar enfermedades autoinmunes e inflamacion cronica.
AR100711A1 (es) Compuestos bicíclicos como agentes para combatir parásitos

Legal Events

Date Code Title Description
FC Refusal